Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by jmm1228 on Oct 09, 2022 5:59pm

BTD and AA

These, when they happen, bring on a new level of expense which TLT must be prepared to handle.
Comment by Eoganacht on Oct 09, 2022 7:14pm
If Theralase gets accelerated approval to commercialize it's side-effect free, efficacious cancer treatment I don't think money will be an issue. Consider some of the long term side effects of existing cancer treatments: Chemotherapy Dental problems Early menopause Hearing loss Heart problems Increased risk of other cancers Infertility Loss of taste Lung disease ...more  
Comment by jmm1228 on Oct 09, 2022 8:05pm
Not smart to have a seat in a high stakes game on a shoestring, is it? I believe we agree on much, but when you wade into a vital fray you need to make sure you don't run out of ready cash. GLTA  
Comment by Infinity on Oct 09, 2022 9:39pm
I have no clue how you came out of the woodwork to pump this management.
Comment by ScienceFirst on Oct 10, 2022 3:51am
Infinity ... It shows you never delivered much in your life, just by your pathetic reasoning.  So easy for you to assume everything is easy to manage.   The reality is that this management team that you bash on delivered so far more disruptive efficacy than any big pharmas have been able to do over the last 40y with their illimited resources.  All this with little investments ...more  
Comment by Infinity on Oct 10, 2022 4:27am
Hey Science first,  You have no clue what you are talking about me or what I have delivered so far.  I do not respond to imbecile comments
Comment by ScienceFirst on Oct 10, 2022 4:33am
Infinity ... By chance, TLT is not run by you!  We would have lost our investment a while ago.
Comment by Infinity on Oct 09, 2022 10:13pm
Hey JMM1228.  I have no idea where you came from to support the current management of TLT,  frakly,  you can pump as much as you want.   Have you tried to get into this Private placement?  Try calling the management or their so called advisors for this PP who are getting paid by the share holders
Comment by Benedictus on Oct 10, 2022 1:46am
  BTD confirmation would catalyze the sp. 77M .35c warrants would be itm and potentially another 7M .50c wts, so despite not having an acceleration clause, I'd still imagine many holders would be highly motivated to exercise and the money will flow into company coffers. This current raise shores up cash concerns for roughly one year if cash burn rate follows recent quarterly trends ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250